bioMérieux reports sales of 965 million euros for the first quarter of 2024, up 6.6% on a reported basis and 9.8% at constant exchange rates and scope of consolidation, with organic growth ahead of expectations.

"The 14% growth in sales of Biofire panels and the promising launch of the Spotfire solution illustrate the ever-growing interest in the syndromic approach", stresses CEO Pierre Boulud, also pointing to the performance in microbiology (+9%).

The in vitro diagnostics specialist confirms its targets for 2024 of organic sales growth of between +6 and +8%, and growth in profit from recurring operations of at least +10% at constant exchange rates.

Copyright (c) 2024 CercleFinance.com. All rights reserved.